Barclays launches U.S. biopharma coverage with four preferred picks

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. COF
10. GOOGL

Go back to Barclays launches U.S. biopharma coverage with four preferred picks

BofA on Eli Lilly (LLY): 'Novo’s GLP-1 price update unlikely to ‘rock the boat’'

February 24, 2026 10:11 AM EST

BofA Securities analyst Tim Anderson reiterated a Buy rating and $1,293.00 price target on Eli Lilly (NYSE: LLY).

The analyst comments "Todays announcement that Novo Nordisk (covered by Sachin Jain) plans to slash GLP-1 list prices offers a flashy headline, but in our view the update is unlikely to have any material impact on the US market. The price announcement is relevant only to commercial insurance channel (est. 30% of 25... More

Novo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ

February 24, 2026 7:41 AM EST

Novo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ

"Under the changes, both Ozempic and Wegovy will list for $675 a month, effective Jan. 1, 2027. That is half of the current price tag for anti-obesity therapy Wegovy and a 34% cut for diabetes treatment Ozempic. The... More